BioAtla Inc. (BCAB)
0.48
-0.02 (-4.00%)
At close: Jan 15, 2025, 3:59 PM
0.49
3.04%
After-hours Jan 15, 2025, 07:50 PM EST
undefined% (undefined)
| Bid | 0.47 |
| Market Cap | 27.85M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.7 |
| PE Ratio (ttm) | -0.28 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 0.49 |
| Volume | 888,606 |
| Avg. Volume (20D) | 1,143,757 |
| Open | 0.50 |
| Previous Close | 0.50 |
| Day's Range | 0.47 - 0.52 |
| 52-Week Range | 0.45 - 4.02 |
| Beta | undefined |
About BCAB
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, mel...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 16, 2020
Employees 65
Stock Exchange NASDAQ
Ticker Symbol BCAB
Website https://www.bioatla.com
Analyst Forecast
According to 2 analyst ratings, the average rating for BCAB stock is "Hold." The 12-month stock price forecast is $5, which is an increase of 941.67% from the latest price.
Buy 50.00%
Hold 50.00%
Sell 0.00%
3 weeks ago ·
Source
-41.82%
BioAlta shares are trading lower after the company...
Unlock content with
Pro Subscription
2 months ago ·
Source
-14.07%
BioAtla shares are trading lower. The stock may be reacting to the Scion Asset Management 13F filing disclosing an exit from their position in the company.
